Skip to content
Review Open access

From receptor biology to therapy: importance of different EGFR mutations in the development of targeted cancer therapies.

Sep 2026 · Immunotherapy · pp. 1-36 · 0 citations · 232 references
Medicine

TL;DR

The role of EGFRvIII in driving aggressive tumor growth is discussed and how effective targeting of EGFRvIII, and overcoming resistance mutations will be crucial to improve EGFR- and EGFRvIII-based therapies are highlighted.

Abstract

Cancer is a leading cause of death globally, and traditional therapies including chemotherapy and radiotherapy are often constrained by systemic toxicity and lack of specificity. Thus, targeted therapies are the need of the hour to revolutionize cancer treatment by enhancing specificity and selectivity, and minimizing off-target effects. The epidermal growth factor receptor (EGFR) and its deletion mutant EGFRvIII exhibit pivotal roles in tumorigenesis, making them attractive targets across multiple cancers. Various targeted therapies, including small-molecule inhibitors, therapeutic antibodies, antibody-drug conjugates, and immunotherapies, are developed to target EGFR, EGFRvIII, and other clinically relevant EGFR mutations, namely L858R, C797S, and T790M. U.S. FDA has approved many of these agents as monotherapies or in conjunction with chemotherapy for treating lung, head and neck, and colorectal cancers; however, there are challenges. In this review, we discuss the role of EGFRvIII in driving aggressive tumor growth and highlight how effective targeting of EGFRvIII, and overcoming resistance mutations will be crucial to improve EGFR- and EGFRvIII-based therapies. The ongoing evolution of these interventions holds promise for long-term responses, reduced toxicity, and enhanced patient survival. Literature related to EGFR- and EGFRvIII-based therapies was searched systematically in PubMed, MEDLINE, Scopus, ScienceDirect, and Google Scholar up to June 2026.

Read PDF

Similar papers

Review Sep 2026

Emerging Therapies in Lung Cancer: A Review on Targeted and Immune Based Interventions.

This review encapsulates significant developments in molecularly targeted agents and immune checkpoint inhibitors, emphasising their clinical efficacy, resistance mechanisms, and innovative therapeutic combinations, and reviews pivotal clinical trials and newly filed patents.

K. C. Geervani, R. Maddileti, Kalpi Sania Kausar et al. · 0 citations
Review Sep 2026

Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.

A major focus of this review is antibody-drug conjugates (ADCs) targeting novel surface antigens, including HER2, HER3, and TROP2, which have demonstrated remarkable clinical efficacy in EGFR TKI-resistant settings.

Xin-Ran Chen, Jia-Qi Liang, Jun-Kan Zhu et al. · 0 citations
Review Sep 2026

Targeted Therapeutics in Breast Cancer: Promise, Progress, and the Challenge of Triple-negative Subtype.

Advances in targeted and immune-based therapies are transforming breast cancer care and Leveraging molecular insights, particularly for TNBC, is crucial to delivering personalised, clinically meaningful treatments and improving outcomes across all subtypes.

S. Sengupta, Ruhi Arisha, Kamal Shah et al. · 0 citations
Review Open access Aug 2026

Antibody–Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges

The rationale for targeting established and emerging antigens in non-small cell and small cell lung cancer, including HER2, TROP2, c-MET, HER3, CEACAM5, DLL3, and other promising targets currently under clinical investigation are discussed.

P. Paliogiannis, G. Fara, A. Zinellu et al. · 0 citations
Review Open access Sep 2026

Mechanisms of Resistance to Targeted Therapy in Epidermal Growth Factor Receptor (EGFR)- and Anaplastic Lymphoma Kinase (ALK)-Mutated Non-small Cell Lung Cancer: Molecular Basis, Emerging Biomarkers, and Therapeutic Strategies

Currently, with the spectacular achievement of the tyrosine kinase inhibitors (TKIs), non-small cell lung cancer (NSCLC) carrying mutations of the gene epidermal growth factor receptor (EGFR) and rearrangements of the gene anaplastic lymphoma kinase (ALK) is becoming a paradigm of precision oncology. While there has be...

S. Dhillon, H. Rathod, Sagar Dhillon · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.